Slides
Page 1
1 Medical Solutions Engineered SolutionsThird quarter CEO Anders Björklund CFO Per-Ola Holmström October 29, 2026
Page 2
Q3 Summary – Nolato Group 2 SEKm A global solutions provider established on three continents 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 R12M ● Sales rose by 7% to SEK 2,500 million (2,342) - Organic growth of 3% adjusted for currency and acquisitions * Medical Solutions +9% * Engineered Solutions -3% * Both acquisitions that were communicated previously were consolidated as of September 1 and contributed SEK 56 million ● Operating profit (EBITA) was SEK 254 million (281) - Adjusted profit SEK 262 million (274) ● Adjusted EBITA margin of 10.5% (11.7) - Adversely affected by increased raw material prices, high costs for start-ups, and customers’ model changes ● Cash flow from operating activities increased to SEK 332 million (301) ● Strong financial position with net financial liabilities in relation to EBITDA of 1.0x (0.5)
Page 3
Nolato strengthens its offering through two strategic acquisitions Unitron and Qualtech bring complementary expertise and capacity in electronics-intensive medical technology, systems integration and advanced manufacturing 3 Qualtech SALES EMPLOYEES EBITA MARGIN approx. SEKm 385 approx. 200 On par with Nolato Brings PCB manufacturing, cable assemblies, testing, procurement and box build, as well as presence in Galway’s medical cluster and a platform for selected security and defense applications. Unitron SALES EMPLOYEES EBITA MARGIN approx. SEKm 200 approx. 100 On par with Nolato Strengthens Medical Solutions with electronics-intensive products, regulatory support and development-centric manufacturing – from design and industrialization to scaled-up production. Common strategic importance Together, these acquisitions broaden Nolato’s offering from product concept and development to industrialization, system integration and mass production – with regulatory support. They enhance capabilities for earlier involvement in customers’ development, taking on greater responsibility in the value chain and growth in attractive, regulated segments.
Page 4
One Group – two Business Areas Nolato Our offering as a strategic partner for selected global customers comprises development and production, primarily in the field of polymers, along the entire value chain. 254 EBITA-RESULT, SEKm Q3 10.2 EBITA-MARGIN, % Q3 2,500 SALES, SEKm Q3 4 Medical Solutions Advanced components, subsystems and complete products are developed and manufactured for medical technology, pharmaceuticals and diagnostics, with high requirements for quality, safety and regulatory compliance. 166 EBITA-RESULT, SEKm Q3 11.3 EBITA-MARGIN, % Q3 1,469 SALES, SEKm Q3 Engineered Solutions Design, development, industrialization and manufacture of advanced components, subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. 112 EBITA-RESULT, SEKm Q3 10.8 EBITA-MARGIN, % Q3 1,040 SALES, SEKm Q3
Page 5
Drug delivery Endoscopy & general surgery Cardiology In vitro diagnostics (IVD) Pharma packagingContinence care Other Medical DevicesDiagnosticsPharma Medical Solutions – focused product areas 5
Page 6
SEKm SEKm % Sales EBITA EBITA margin Medical Solutions – Q3 Sales per market area, Q3 6 Drug delivery, 19% (18) Endoscopy & general surgery 19% (21) Pharmaceutical packaging, 11% (10) Other, 15% (15) Continence care, 11% (13) In vitro diagnostics, 18% (17) Cardiology, 7% (6) Q3 Acc. 9 months SEKm 2026 2025 2026 2025 Sales 1,469 1,311 4,202 4,062 Operating profit (EBITA) 166 159 487 500 EBITA margin (%) 11.3 12.1 11.6 12.3 Operating profit (EBIT) 158 152 465 478 ● Sales rose by 12%, amounting to SEK 1,469 million (1,311) - Adjusted for currency and acquisitions, organic growth of a full 9% - Drug delivery continued its upbeat performance, driven by increased volumes for major customer projects in Hungary and the US - The In vitro diagnostics (IVD) market segment increased with a higher proportion of new products - Other market areas had stable volumes ● EBITA margin of 11.3% (12.1) - Negative impact in the quarter from growth in newer products that have not yet reached planned volumes, but with resources and costs designed for higher volumes, affected the margin ● Expansion in Hungary and the US linked to significant customer contracts is proceeding according to plan - Gradually increased delivery capacity according to schedule - Supports the Group's growth targets 0 200 400 600 800 1000 1200 1400 1600 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 0 20 40 60 80 100 120 140 160 180 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 0 2 4 6 8 10 12 14 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26
Page 7
Materials Automotive Consumer electronics Other Hygiene Engineered Solutions – focused product areas 7
Page 8
Engineered Solutions – Q3 SEKm SEKm % SALES EBITA EBITA margin Sales per market area, Q3 Automotive, 17% (22) Hygiene, 14% (15) Consumer electronics, 13% (14) Other, 33% (31) Materials, 23% (18) 8 Q3 Acc. 9 months SEKm 2026 2025 2026 2025 Sales 1,040 1,035 3,130 3,137 Operating profit (EBITA) 112 120 330 344 EBITA margin (%) 10.8 11.6 10.5 11.0 Operating profit (EBIT) 108 118 320 336 0 200 400 600 800 1000 1200 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 0 20 40 60 80 100 120 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 0 2 4 6 8 10 12 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 ● Sales totaled SEK 1,040 million (1,035) - A decrease of 3% adjusted for currency and acquisitions - Strong growth for Materials, which grew as much as 27%; all customer segments showed growth - The Consumer electronics market segment exhibited stable volumes - Hygiene had lower volumes, affected by inventory adjustments and lower demand, albeit with a sequential improvement - The Automotive area saw a sharp decline with lower demand and model changes among customers - Increase in Other due to acquisitions ● EBITA margin of 10.8% (11.6) - Negative impact from price increases for raw materials driven by oil prices (lag) - Model changes in Automotive had a negative impact - Favorable product mix with a higher proportion of Materials
Page 9
Group financial highlights 9 SEKm Q3 2026 Q3 2025 Acc. 9 months 2026 2025 R12M Full yr. 2025 Net sales 2,500 2,342 7,311 7,190 9,583 9,462 Operating profit (EBITA) 254 281 761 829 997 1,065 Adjusted operating profit (EBITA) 262 274 769 822 1,005 1,058 EBITA margin (%) 10.2 12.0 10.4 11.5 10.4 11.3 Adjusted EBITA margin (%) 10.5 11.7 10.5 11.4 10.5 11.2 Profit after financial income and expense 224 257 676 773 886 983 Profit after tax 172 215 522 626 673 777 Effective tax (%) 23.2 16.3 22.8 19.0 24.0 21.0 Cash flow from operating activities 332 301 844 752 1,154 1,062 Net investments affecting cash flow, excl. acquisitions and disposals 191 183 517 642 663 788 Cash flow after investments, excl. acquisitions and disposals 141 118 327 110 297 274 Earnings per share (SEK) 0.64 0.80 1.94 2.32 2.50 2.88 Equity/assets ratio (%) – – 53 59 53 60 Net financial liabilities, excl. pension & lease liabilities – – 1,537 928 1,537 756 Return on capital employed (%) – – 12.4 14.1 12.4 14.2 Net financial liabilities in relation to adjusted EBITDA (x) – – – – 1.0 0.5
Page 10
Current trading 10 Favorable financial position enables intensified M&A agenda • Continued growth strategy – high market activity • Innovation and sustainability • Broad customer base with longstanding, close customer relationships • Major client contracts confirm the overall strategy • Establishment of operations in Malaysia and expansion in Poland Medical Solutions Engineered Solutions • Advanced market positions, not least in Consumer electronics and Materials • Established position in new product areas • Focus on innovative and sustainable solutions • Success in new products and technology areas, mainly data centers, positive for Materials • Expansion of the operations in Malaysia
Page 11
This presentation may contain forward-looking statements. When used in this presentation, words such as “anticipate”, “believe”, “estimate”, “expect”, “plan” and “project” are intended to identify forward-looking statements. Such statements could encompass risks and uncertainties pertaining to product demand, market acceptance, effects of economic conditions, impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nolato’s management as of the date made with respect to future events but are subject to risks and uncertainties. While all of these forward-looking statements are based on estimates and assumptions made by Nolato’s management and are believed to be reasonable, they are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. Nolato disclaims any intention or obligation to update these forward-looking statements. Thank you! 11